PROCHLORPERAZINE

Post-LOE

prochlorperazine

Design Pharmaceuticals

ANDARECTALSUPPOSITORY

Approved

Jul 2001

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

PROCHLORPERAZINE (prochlorperazine) by Design Pharmaceuticals is clinical pharmacology prochlorperazine is a propylpiperazine derivative of phenothiazine. Approved for schizophrenia. First approved in 2001.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Prochlorperazine is a propylpiperazine derivative of phenothiazine. Like other phenothiazines, it exerts an antiemetic effect through a depressant action on the chemoreceptor trigger zone.

Indications (1)

schizophrenia

Clinical Trials (3)

NCT06450899Phase 2Completed

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Started Aug 2024

57 enrolled

Acute Mountain Sickness

NCT02779959Phase 3Unknown

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

Started Apr 2016

80 enrolled

Migraine Disorders

NCT00573599N/AWithdrawn

Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department

Started Feb 2007

Acute Migraine Headache

Worked on PROCHLORPERAZINE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.